Q3 EPS Estimates for Ovid Therapeutics Increased by B. Riley

Ovid Therapeutics (NASDAQ:OVID) – Research analysts at B. Riley upped their Q3 2025 EPS estimates for shares of Ovid Therapeutics in a note issued to investors on Wednesday, August 13th. B. Riley analyst M. El-Saadi now forecasts that the company will post earnings of ($0.12) per share for the quarter, up from their previous forecast of ($0.16). B. Riley currently has a “Buy” rating and a $3.00 target price on the stock. The consensus estimate for Ovid Therapeutics’ current full-year earnings is ($0.40) per share. B. Riley also issued estimates for Ovid Therapeutics’ Q4 2025 earnings at ($0.12) EPS, FY2025 earnings at ($0.45) EPS, FY2026 earnings at ($0.59) EPS, FY2027 earnings at ($0.65) EPS, FY2028 earnings at ($0.72) EPS and FY2029 earnings at ($0.81) EPS.

Several other equities analysts have also weighed in on OVID. William Blair upgraded shares of Ovid Therapeutics to a “strong-buy” rating in a report on Thursday, April 24th. HC Wainwright reduced their target price on shares of Ovid Therapeutics from $2.00 to $1.50 and set a “buy” rating on the stock in a report on Tuesday, May 27th. Finally, Wall Street Zen upgraded shares of Ovid Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $3.10.

Ovid Therapeutics Stock Performance

NASDAQ:OVID opened at $0.97 on Monday. The company has a current ratio of 4.72, a quick ratio of 4.72 and a debt-to-equity ratio of 0.23. The firm has a market capitalization of $68.98 million, a price-to-earnings ratio of -1.83 and a beta of 0.20. The firm’s fifty day simple moving average is $0.45 and its 200 day simple moving average is $0.42. Ovid Therapeutics has a twelve month low of $0.24 and a twelve month high of $1.47.

Ovid Therapeutics (NASDAQ:OVID) last announced its quarterly earnings data on Wednesday, August 13th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.10. The company had revenue of $6.27 million during the quarter, compared to analysts’ expectations of $0.09 million. Ovid Therapeutics had a negative net margin of 574.44% and a negative return on equity of 58.87%.

Hedge Funds Weigh In On Ovid Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. Rosalind Advisors Inc. acquired a new position in Ovid Therapeutics in the 2nd quarter worth $165,000. Jane Street Group LLC acquired a new position in Ovid Therapeutics in the 2nd quarter worth $47,000. Velan Capital Investment Management LP lifted its holdings in Ovid Therapeutics by 64.9% in the 2nd quarter. Velan Capital Investment Management LP now owns 160,000 shares of the company’s stock worth $53,000 after buying an additional 63,000 shares in the last quarter. Marshall Wace LLP acquired a new position in Ovid Therapeutics in the 2nd quarter worth $54,000. Finally, Y Intercept Hong Kong Ltd acquired a new position in Ovid Therapeutics in the 2nd quarter worth $53,000. Institutional investors and hedge funds own 72.24% of the company’s stock.

About Ovid Therapeutics

Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies.